The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605).
 
Neil Shah
Honoraria - MJH Life Sciences
Consulting or Advisory Role - Merck Sharp & Dohme Corp.
Research Funding - Aravive (Inst); Exelixis; HiberCell (Inst)
Travel, Accommodations, Expenses - Merck
 
Manojkumar Bupathi
Honoraria - Agendia; AIQ Solutions; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; EMD Serono; Exelixis; Exelixis; Exelixis; Exelixis; Janssen; Myovant Sciences; Pfizer
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Exelixis
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Exelixis; Janssen Oncology; Pfizer
 
Benjamin Garmezy
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); crispr therapeutics (Inst); Eikon Therapuetics (Inst); Envision Pharma Group (Inst); Exelixis (Inst); Flare Therapeutics (Inst); Genentech (Inst); Harbour BioMed (Inst); IDEAYA Biosciences (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jubilant Therapeutics (Inst); Kineta (Inst); Kinnate Biopharma (Inst); Loxo (Inst); Loxo/Lilly (Inst); MiNK Therapeutics (Inst); Nuvation Bio (Inst); ProfoundBio (Inst); Roche/Genentech (Inst); Takeda (Inst); Teon Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Xencor (Inst); Zenshine (Inst); Zenshine (Inst)
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Adaptimmune (Inst); Adicet Bio (Inst); AIQ Global (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); Exelixis (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Rondo Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Xencor (Inst)
 
Rana McKay
Consulting or Advisory Role - Ambrx; Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; NeoMorph; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)
 
Moshe Ornstein
Consulting or Advisory Role - AVEO; Bristol Myers Squibb Foundation; Eisai; Exelixis; Merck; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Merck
Research Funding - Aravive (Inst); Arcus Biosciences (Inst); Astellas Medivation (Inst); AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); HiberCell (Inst); Merck (Inst); Pfizer (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Exelixis; Merck; Pfizer
 
Robert Figlin
Employment - 4D Medical
Leadership - 4D Medical; 4Dx
Stock and Other Ownership Interests - 4Dx
Consulting or Advisory Role - Johnson & Johnson
Research Funding - Merck (Inst)
 
Joel Picus
Research Funding - lava therapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Brian Rank
Employment - HealthPartners, Inc
 
Pedro Barata
Honoraria - UroToday
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; AVEO; Bayer; BMS; Caris Life Sciences; Dendreon (Inst); Eisai; EMD Serono; Exelixis; Ipson; Merck; Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Bayer (Inst); Caris Life Sciences (Inst); Merck; Pfizer/Astellas (Inst)
Research Funding - AVEO (Inst); Blue Earth Diagnostics (Inst); Exelixis; Merck (Inst); Pfizer (Inst)
 
Hans Hammers
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - ARMO BioSciences; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; exelixis; Lilly; Merck; Novartis; Pfizer; Surface Oncology
Research Funding - aravive (Inst); Aveo (Inst); Bristol-Myers Squibb (Inst); Hibercell (Inst); Merck (Inst); NGM Biopharmaceuticals (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Novartis; Pfizer
 
Thomas Hutson
Employment - Texas Oncology
Honoraria - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Johnson & Johnson (Inst); Pfizer (Inst)
 
Elaine Lam
Consulting or Advisory Role - Pathos
Research Funding - Amgen (Inst); Arrowhead Pharmaceuticals (Inst); Astellas Pharma (Inst); Biosplice (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Decibel Therapeutics (Inst); Exelixis (Inst); FORMA Therapeutics (Inst); Harpoon Therapeutics (Inst); Hibercell (Inst); Merck (Inst); OnQuality Pharmaceuticals (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Roche/Genentech (Inst)
 
Scott Tykodi
Honoraria - CancerNetwork; FirstWord; OncLive/MJH Life Sciences; Targeted Oncology; Topline Bio
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Exelixis
Research Funding - AVEO (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); HiberCell (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Nektar (Inst); Pfizer (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending (Inst)
 
Song Zhao
Consulting or Advisory Role - AstraZeneca; Janssen Oncology
Research Funding - Merck Sharp & Dohme (Inst); Pfizer (Inst)
 
Hamid Emamekhoo
Consulting or Advisory Role - AVEO; Bristol Myers Squibb company; Cardinal Health; Cardinal Health; Eisai; Janssen Biotech; Janssen Biotech
 
Michael Chisamore
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Paulette Mattson
Employment - HiberCell
Stock and Other Ownership Interests - HiberCell
 
Megan Holm
Stock and Other Ownership Interests - Glaco Smith Kline (I)
 
Jose Iglesias
Consulting or Advisory Role - Amplia Therapeutics; Carina; Duo Oncology; Engione Bio; Epsilogen; HiberCell; Panavance Therapeutics
Travel, Accommodations, Expenses - Carina
 
Robert Motzer
Consulting or Advisory Role - Aveo; EMD Serono; Exelixis; Incyte; Merck; Takeda
Research Funding - Aveo (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb